Marketed drugs based on exendin-4 are exenatide and lixisenatide (Figure 1)
GLP-1 Medications and Weight Loss: More Than Just Appetite Suppression Lets start with the basics
In the years ending December 31, 2023 and 2022, the Company received refundable research and development credits from foreign tax authorities of approximately $ At December 31, 2023 and 2022, the Company had federal net operating loss carryforwards of approximately $ Significant components of the Companys net deferred tax asset are as follows: The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and development (R&D) expenditures under section 174 for tax years beginning after December 31, 2021
We intend to provide comprehensive insights and guidance on this nuanced topic in order to alleviate concerns and provide understanding for you to embark upon the next necessary steps of your healthcare journey with confidence
It's perfect for adults dealing with obesity or those who are overweight and have weight-related conditions
However, research shows that weight regain is common after stopping GLP-1 treatment, especially without a clear plan and continued support
